Dafna Bar-Sagi

Dafna Bar-Sagi

Auto-generated profile, based on publicly available information

Dafna Bar-Sagi

Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2013 in Nature
Verified
Journal Article
Open access
PDF file
CCCosimo Commisso
Cosimo Commisso
SDShawn M. Davidson
Shawn M. Davidson
RSRengin G. Soydaner-Azeloglu
Rengin G. Soydaner-Azeloglu
SPSeth Parker
Seth Parker
JKJurre J. Kamphorst
Jurre J. Kamphorst
DBDafna Bar-Sagi
Dafna Bar-Sagi
Oncogenic Ras has previously been shown to promote macropinocytosis; here it is demonstrated that this process allows tumour cells to use extracellular proteins to generate amino acids necessary to support tumour growth. This paper describes a previously unrecognized pathway of nutrient supply to cancer cells. Oncogenic Ras proteins are known to promote macropinocytosis, an endocytic process by which extracellular fluid and its contents are internalized into cells through vesicles known as macropinosomes. Dafna Bar-Sagi and colleagues now demonstrate that Ras-transformed cells can use this process to 'feed' on extracellular protein. The macropinocytosed protein undergoes degradation, giving rise to free amino acids necessary to support tumour growth. This finding suggests that inhibition of macropinocytosis may be effective against a subset of cancers. Macropinocytosis is a highly conserved endocytic process by which extracellular fluid and its contents are internalized into cells through large, heterogeneous vesicles known as macropinosomes. Oncogenic Ras proteins have been shown to stimulate macropinocytosis but the functional contribution of this uptake mechanism to the transformed phenotype remains unknown1,2,3. Here we show that Ras-transformed cells use macropinocytosis to transport extracellular protein into the cell. The internalized protein undergoes proteolytic degradation, yielding amino acids including glutamine that can enter central carbon metabolism. Accordingly, the dependence of Ras-transformed cells on free extracellular glutamine for growth can be suppressed by the macropinocytic uptake of protein. Consistent with macropinocytosis representing an important route of nutrient uptake in tumours, its pharmacological inhibition compromises the growth of Ras-transformed pancreatic tumour xenografts. These results identify macropinocytosis as a mechanism by which cancer cells support their unique metabolic needs and point to the possible exploitation of this process in the design of anticancer therapies.

13 October 2011 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
YPYuliya Pylayeva-Gupta
Yuliya Pylayeva-Gupta
EGElda Grabocka
Elda Grabocka
DBDafna Bar-Sagi
Dafna Bar-Sagi

1 June 2012 in Cancer Cell
Verified
Journal Article
Closed access
YPYuliya Pylayeva-Gupta
Yuliya Pylayeva-Gupta
KLKyoung Eun Lee
Kyoung Eun Lee
CHCristina H. Hajdu
Cristina H. Hajdu
GMGeorge Miller
George Miller
DBDafna Bar-Sagi
Dafna Bar-Sagi

1 March 2016 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YPYuliya Pylayeva-Gupta
Yuliya Pylayeva-Gupta
SDShipra Das
Shipra Das
JHJesse S. Handler
Jesse S. Handler
CHCristina H. Hajdu
Cristina H. Hajdu
MCMaryaline Coffre
Maryaline Coffre
DBDafna Bar-Sagi
Dafna Bar-Sagi
A salient feature of pancreatic ductal adenocarcinoma (PDAC) is an abundant fibroinflammatory response characterized by the recruitment of immune and mesenchymal cells and the consequent establishment of a protumorigenic microenvironment. Here, we report the prominent presence of B cells in human pancreatic intraepithelial neoplasia and PDAC lesions as well as in oncogenic Kras-driven pancreatic neoplasms in the mouse. The growth of orthotopic pancreatic neoplasms harboring oncogenic Kras was significantly compromised in B-cell–deficient mice (μMT), and this growth deficiency could be rescued by the reconstitution of a CD1dhiCD5+ B-cell subset. The protumorigenic effect of B cells was mediated by their expression of IL35 through a mechanism involving IL35-mediated stimulation of tumor cell proliferation. Our results identify a previously unrecognized role for IL35-producing CD1dhiCD5+ B cells in the pathogenesis of pancreatic cancer and underscore the potential significance of a B-cell/IL35 axis as a therapeutic target. Significance: This study identifies a B-cell subpopulation that accumulates in the pancreatic parenchyma during early neoplasia and is required to support tumor cell growth. Our findings provide a rationale for exploring B-cell–based targeting approaches for the treatment of pancreatic cancer. Cancer Discov; 6(3); 247–55. ©2015 AACR. See related commentary by Roghanian et al., p. 230. See related article by Lee et al., p. 256. See related article by Gunderson et al., p. 270. This article is highlighted in the In This Issue feature, p. 217

1 July 2017 in Cell Reports
Verified
Journal Article
Open access
JJJung-Eun Jang
Jung-Eun Jang
CHCristina H. Hajdu
Cristina H. Hajdu
CLCaroline Liot
Caroline Liot
GMGeorge Miller
George Miller
MDMichael Dustin
Michael Dustin
DBDafna Bar-Sagi
Dafna Bar-Sagi
Regulatory T (Treg) cell infiltration constitutes a prominent feature of pancreatic ductal adenocarcinoma (PDA). However, the immunomodulatory function of Treg cells in PDA is poorly understood. Here, we demonstrate that Treg cell ablation is sufficient to evoke effective anti-tumor immune response in early and advanced pancreatic tumorigenesis in mice. This response is dependent on interferon-γ (IFN-γ)-producing cytotoxic CD8+ T cells. We show that Treg cells engage in extended interactions with tumor-associated CD11c+ dendritic cells (DCs) and restrain their immunogenic function by suppressing the expression of costimulatory ligands necessary for CD8+ T cell activation. Consequently, tumor-associated CD8+ T cells fail to display effector activities when Treg cell ablation is combined with DC depletion. We propose that tumor-infiltrating Treg cells can promote immune tolerance by suppressing tumor-associated DC immunogenicity. The therapeutic manipulation of this axis might provide an effective approach for the targeting of PDA.

8 January 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
SDShipra Das
Shipra Das
BSBeny Shapiro
Beny Shapiro
EVEmily A. Vucic
Emily A. Vucic
SVSandra Vogt
Sandra Vogt
DBDafna Bar-Sagi
Dafna Bar-Sagi
Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy typified by a highly stromal and weakly immunogenic tumor microenvironment that promotes tumor evolution and contributes to therapeutic resistance. Here, we demonstrate that PDA tumor cell–derived proinflammatory cytokine IL1β is essential for the establishment of the protumorigenic PDA microenvironment. Tumor cell–derived IL1β promoted the activation and secretory phenotype of quiescent pancreatic stellate cells and established an immunosuppressive milieu mediated by M2 macrophages, myeloid-derived suppressor cells, CD1dhiCD5+ regulatory B cells, and Th17 cells. Loss of tumor cell–derived IL1 signaling in tumor stroma enabled intratumoral infiltration and activation of CD8+ cytotoxic T cells, attenuated growth of pancreatic neoplasia, and conferred survival advantage to PDA-bearing mice. Accordingly, antibody-mediated neutralization of IL1β significantly enhanced the antitumor activity of α-PD-1 and was accompanied by increased tumor infiltration of CD8+ T cells. Tumor cell expression of IL1β in vivo was driven by microbial-dependent activation of toll-like receptor 4 (TLR4) signaling and subsequent engagement of the NLRP3 inflammasome. Collectively, these findings identify a hitherto unappreciated role for tumor cell–derived IL1β in orchestrating an immune-modulatory program that supports pancreatic tumorigenesis.Significance: These findings identify a new modality for immune evasion in PDA that depends on IL1β production by tumor cells through TLR4-NLRP3 inflammasome activation. Targeting this axis might provide an effective PDA therapeutic strategy.